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Objective: To assess a walking model utilizing a set of standardized treadmill walks to measure acute
analgesic response in osteoarthritis (OA) of the knee.
Design: Randomized, double-blind, placebo-controlled, multiple dose, three-period crossover study.
Patients 45 years of age (N¼ 22) with symptomatic knee OA were randomized to naproxen 500 mg bid,
tramadol/acetaminophen 37.5 mg/325 mg in forced titration, or placebo in each of three periods. Patients
performed multiple 20-minute treadmill walks on Day 1 and Day 3 at a consistent self-selected pace
predetermined at screening. Pain intensity (PI) during the walks was assessed on an 11-point numerical
rating scale at 0, 3, 6, 9, 12, 15, 18, and 20 min. The primary endpoint was the time-weighted average
(TWA) change from baseline PI on Day 3 for the two self-paced walks for the active treatments vs
placebo. Time to moderate pain (TTMP) was a key secondary endpoint.
Results: Compared with placebo, the TWA change from baseline PI on Day 3 was signiﬁcantly better with
tramadol/acetaminophen (P¼ 0.043) but not with naproxen (P¼ 0.089). TWA change from baseline on
Day 1 was also signiﬁcantly better with both tramadol/acetaminophen (P¼ 0.001) and naproxen
(P¼ 0.048) compared with placebo. TTMP was signiﬁcantly better for tramadol/acetaminophen and
naproxen than placebo (P< 0.001 to P¼ 0.015) for walks on Day 1 after a single dose and on Day 3.
Conclusions: This novel OA pain model was able to discriminate both tramadol/acetaminophen and
naproxen from placebo after single and multiple doses.
ClinicalTrials.gov identiﬁer: NCT00772967.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is a chronic disease1. As such, most trials
evaluating nonsteroidal anti-inﬂammatory drugs (NSAIDs) in OA
have primary endpoints reﬂecting chronic therapy (e.g., 6
weeks)2. Indeed, regulatory guidance recommends OA analgesia
trials be 3 months in duration3. However, despite the chronic
nature of OA, the clinical course can be variable, with treatment
needed only during exacerbations, often brought on by physical
activity1. This treatment pattern generally is conﬁrmed byElena Peeva, Merck Research
ay, NJ 07065, United States.
a).
aper.
s Research Society International. Pprescription patterns, showing that patients with OA receive only
a few prescriptions each year, each for only approximately 1 month
treatment4e6. Thus, despite the chronic nature of OA, pain is often
treated on a more acute, as-needed basis.
Trials of NSAIDs in acute pain models7e9 routinely evaluate
acute onset of analgesia, but suchmeasures of early onset are rarely
assessed in OA NSAID trials10e13, although it is not uncommon to
evaluate the effect in the ﬁrst days or week of treatment14e16. Thus,
there appear to be gaps among disease course, treatment patterns,
and trial design in OA. Speciﬁcally, there appears to be a need to
better assess acute onset of analgesia in OA.
Moskowitz and colleagues demonstrated a proof-of-concept
walking model to assess acute analgesia in OA, showing signiﬁcant
effect with single-dose rofecoxib or valdecoxib compared with
placebo11. We developed awalking model using multiple walks and
a crossover design to evaluate single- and multiple-dose effects ofublished by Elsevier Ltd. All rights reserved.
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tramadol/acetaminophen).
Methods
This was a randomized, double-blind, placebo-controlled, three-
period crossover study conducted at two sites in the United States
from June 2008 to November 2008. The protocol (Merck protocol
105) and study procedures were conducted in accordance with the
principles of the Declaration of Helsinki and Good Clinical Practice
Guidelines, regarding the protection of the rights and welfare of
human subjects participating in biomedical research, and were
approved by appropriate institutional review boards. Written
informed consent was obtained for all patients before study
enrollment.
Patients
Patientswere45years of agewithkneeOA>6monthsbasedon
clinical and radiographic criteria and had an American Rheumato-
logical Association functional class of IeIII. Patientswere required to
be taking analgesics for knee pain for 15 days in the previous 30
days, with a self-reported history of positive therapeutic beneﬁt
with NSAIDs, cyclo-oxygenase-2 (COX-2) inhibitors, acetamino-
phen, codeine, or tramadol. Eligible patients had pain intensity (PI)
while standing 5 on a 0e10 numeric rating scale (NRS). Patients
met minimum criteria for worsening pain following analgesic
washout: 1) 40 mm on patient-reported pain walking on a ﬂat
surface (Western Ontario and McMaster Universities [WOMAC]
visual analog scale [VAS] 3.0), with an increase 15 mm from
screening value on a 100-mm [VAS]; 2) a worsening investigator
global assessment of disease status (IGADS) 1 point on a 5-point
Likert scale; and 3) a PI score 1 unit higher on the post-washout
treadmill walk than the screening treadmill walk. Patients also
demonstratedPI increase3units during a screening treadmillwalk
above PI measured while standing (at rest). Exclusion criteria
included a history of inﬂammatory arthritis, active gout, intra-
articular fracture, or partial or completearthrodesis orarthroplasyof
the study joint; acute ligamentous or meniscal injury of the study
joint within the previous 2 years or arthroscopy within 6 months;
history of gastrointestinal bleeding or documented ulcer disease in
the past 5 years; uncontrolled hypertension, impaired renal func-
tion, or signiﬁcant hepatic disease; history of dizziness, ataxia,
unsteadiness, or decreased proprioception; history of falling in the
previous 30 days; routine use of a cane or walker for ambulation;
intra-articular steroids within 3 months or hyaluronic acid injec-
tions within 6 months to the study knee; intravenous, intramus-
cular, or oral corticosteroids, intra-articular steroid or hyaluronic
acid injections to any other joint within 1 month; current narcotic
analgesic use other than codeine or tramadol; or any chronic
medication used for less than 1month. Patients taking a stable dose
of glucosamine or chondroitin sulfate were permitted to continue
treatment at the same dose. Patients were permitted to continue
physiotherapy (e.g., physical therapy) throughout the study if begun
at least 1 week prior to screening and did not change in session
duration or frequency during the study. Acetaminophen up to
4000 mg daily was permitted for rescue analgesia during the study,
but use was not permitted within 24 h of study treadmill walks.
Study design
At Visit 1 patients performed a treadmill walk at a pace that was
tobe as fast as they felt theycould safelymaintain for 20 min,with PI
assessed on an 11-point NRS (0¼ “No Pain” and 10¼ “Worst Pain
You Can Imagine”). Patients discontinued analgesic treatments andreturned (Visit 2) after an appropriate washout of 3e15 days based
on the half-life speciﬁc medication(s) and demonstrated worsening
pain as described above. Patients meeting all eligibility criteria
established a self pace (SP) that would be used in all treatment
period SP walks by increasing the treadmill speed from 0 miles per
hour (MPH) to 1 MPH over 15 s, and then 0.4 MPH every 15 s
thereafter until patients walked a brisk, sustainable pace 1 MPH
that could bemaintained for at least 3 min, ﬁguring changes in pain
at a self-selected pacewould bemore reﬂective of the patient's pain
status whenwalking during daily living. A high-pace (HP) treadmill
speedwas also selected; patientswere started at their SP speed, and
the rate was increased until a speed of SPþ 30% was reached. The
highest pace above SP that the patient could walk safely for at least
5 min was the HP. SP and HP walks were each 20 min in duration,
with PImeasured at 0, 3, 6, 9,12,15,18, and 20 min during thewalks.
Study medication was administered in double-dummy fashion
with over-encapsulated pills. Patients received treatments as
multiple oral doses for 3 days in each treatment period. Dosing
occurred twice on Day 1 (morning and evening); three times on
Day 2 (morning, afternoon and evening), and once in the morning
on Day 3. Because tramadol/acetaminophen 37.5/325 mg/mg is
a weak opioid, the dose was titrated over the 3-day study period,
starting with one tablet bid on Day 1, increased to one tablet tid on
Day 2 and reached full dosage of two tablets on the morning of Day
3. Thus, during the tramadol/acetaminophen period, patients
received total daily doses of 75/650 mg/mg on Day 1 and 112.5/
975 mg/mg on Day 2, and 75/650 mg/mg administered as a single
dose on Day 3. Patients received 1000 mg total daily dose of nap-
roxen on Days 1 and 2 and 500 mg on the morning of Day 3.
Allocation to balanced treatment sequences was determined
according to a computer-generated schedule by the study statisti-
cian. Numbered containers were used to implement allocation. All
study personnel, including investigators, study site personnel,
patients, monitors, and central laboratory personnel, were blinded
to treatment allocation throughout the study; the code was
revealed to the researchers once recruitment, data collection, and
laboratory analyses were complete.
The study comprised three 3-day periods, with a 4- to 7-day
washout between periods [Fig. 1(b)]. Treadmill walks were per-
formed on Days 1 and 3 as shown in Fig. 1(a). Each walk was 20 min
long with the patient resting for 40 min between each walk.
Efﬁcacy and safety assessments
The primary efﬁcacy endpoint was the change from baseline in
time-weighted average (TWA) PI for both post-dose SP walks on
Day 3, with TWA reﬂective of pain across the entirewalk. Day 3 was
chosen because a previous walking model in OA had not shown
a signiﬁcant difference between ibuprofen and placebo on TWA PI
on Day 117. Key secondary endpoints included TWA PI for all SP
walks on Day 1 and for each individual walk on Days 1 and 3, the
time to develop moderate pain (TTMP) using a 4-point Likert scale
(none, slight, moderate, severe), and if applicable, the time to
severe pain (TTSP). WOMAC questionnaire VAS 3.0 (100-mm VAS)
was collected at the end of Days 1 and 3 after the completion of the
last timed walks, with patients reporting pain, function, and stiff-
ness results for the preceding 24 h.
The incidence of overall adverse experiences (AEs), serious AEs,
drug-related AEs, and discontinuation due to AEs was collected to
evaluate tolerability and safety.
Statistical methods
The primary hypothesis was that naproxen and/or tramadol/
acetaminophen will have lower TWA PI for SP walks on Day 3 of
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Fig. 1. Study design and timing for dosing and walks in each treatment period. a. Timing for dosing and walks in each treatment period. Times shown represent hours post-initial
dose. *Observed doses administered at the clinic; all other doses administered at home.  Treadmill walks: 20 min each followed by a 40-min rest period. HP: high-pace; SP: self
pace. b. Study design. D¼Day.
Fig. 2. Patient ﬂow through the study.
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based on the two SP walks on Day 3 using all patients who received
at least one dose of study medication and had baseline and at least
one on-treatment observation. Only observed data were analyzed;
no datawere imputed. Baseline was deﬁned as the TWA PI from the
pre-treatment walk on Day 1 of each period. The same endpoint
was assessed for the three SP walks on Day 1 and for each walk
separately. The between-treatment differences were estimated and
tested by the least squares (LS) mean for each endpoint compared
between each active treatment group and placebo using an analysis
of variance model for a 3-period crossover design. The model
included terms for treatment, period, random subject effect, and
baseline value included as covariate. Based on a measured standard
deviation (SD) of 0.9 observed in a previous study (Merck protocol
057; ClinicalTrials.gov Identiﬁer: NCT00565084)17, a sample size of
18 patients provides 80% power to yield a statistically signiﬁcant
(a¼ 0.05) between-treatment difference if the true underlying
difference is 0.9 units on an 11-point NRS. Because each active
treatment was compared with placebo independently, no adjust-
ment for multiplicity was made for the primary endpoint.
After results unblinding, we found that one outlier patient had
exceptionally high PI scores; PI was >3 SD above the mean PI in the
naproxen group for all walks in that treatment period. A review of
the patient's medical history did not reveal trauma, injury, or any
other explanation for his/her unusual response while taking nap-
roxen. The previous walking model with 30 patients treated with
ibuprofen showed no outliers17. Additional post-hoc analyses of our
primary and secondary efﬁcacy measures were carried out
excluding this patient.
Results
Patients
Patient accounting is shown in Fig. 2. Nineteen patients (86.4%)
completed the study, and all 19 were included in both the primary
efﬁcacy analysis and safety analysis. Two patients discontinued due
to protocol violations, and one patient discontinued due to an AE
(acute gouty attack), which was not considered to be drug-related.Most patients were female (63.6%), White (95.5%), and had a mean
age of 59.6 years (Table I).
Efﬁcacy
TWA change in PI
For the primary endpoint, TWA change in PI from baseline on
Day 3 SP walks, tramadol/acetaminophen (LS mean 1.7) had
Table I
Baseline patient demographics
N¼ 22, n (%)
Age (years)
Mean (SD) 59.6 (7.9)
Range 47e73
Gender
Male 8 (36.4)
Female 14 (63.6)
Race
White 21 (95.5)
Black 1 (4.5)
Disease duration (years)
Mean (SD) 8.5 (6.5)
ARA class
I 0 (0.0)
II 20 (90.9)
III 2 (9.1)
Other OA joint involvement
Hand 4 (18.2)
Hip 1 (4.5)
Shoulder 1 (4.5)
Spine 2 (9.1)
Prescreening analgesic use
NSAID 16 (72.7)
COX-2 selective inhibitor 3 (13.6)
Acetaminophen 9 (40.9)
Tramadol/codeine 1 (4.5)
Prestudy WOMAC scores (mm), mean (SD)
Pain subscale 34.7 (12.6)
Stiffness subscale 42.8 (15.7)
Physical function subscale 36.1 (12.4)
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[Table II, Fig. 3(a)]. The comparison between naproxen (1.5) and
placebo was not statistically signiﬁcant (P¼ 0.089). Post-hoc
assessment excluding the outlier subject showed similar mean
responses with reduced variability, such that the TWA PI was
statistically signiﬁcant for both naproxen (1.7; P¼ 0.009) and
tramadol/acetaminophen (2.0; P¼ 0.001) compared with placebo
(0.7) [Fig. 3(b)].
The TWA changes in PI from baseline for SP walks on Day 1 were
1.5 for tramadol/acetaminophen, 1.0 for naproxen, and 0.4 for
placebo (P¼ 0.001 vs tramadol/acetaminophen; P¼ 0.048 vs nap-
roxen) (Table II).
For the HP walks on Day 1, the TWA change in PI was 1.0 for
tramadol/acetaminophen, 0.5 for naproxen, and 0.2 for placebo
(P¼ 0.003 vs tramadol/acetaminophen; P¼ 0.052 vs naproxen). For
Day 3 HPwalks, the results were1.3 for tramadol/acetaminophen,
1.1 for naproxen, and 0.2 for placebo (P¼ 0.007 vs tramadol/
acetaminophen; P¼ 0.019 vs naproxen).Table II
Mean difference from placebo in TWA change from baseline in PI
Self-pace Day 3 Self-pace Day 1
Naproxen
(P-value)
Tramadol/
Acetaminophen
(P-value)
Naproxen
(P-value)
Tramadol/
Acetaminophen
(P-value)
Endpoint (all patients n¼ 22)
0.611 (0.089) 0.804 (0.043) 0.518 (0.048) 1.03 (0.001)
Endpoint (excluding outlier n¼ 21)
0.930 (0.009) 1.28 (0.001) 0.872 (<0.001) 1.32 (<0.001)
All values expressed as LS means.
Self-pace walk results are pooled for each day.
For each of these responses a mixed model (treatment, walk as ﬁxed effects, subject as ra
placebo.Mean PI responses for each walk demonstrated increasing pain
during each 20 min walk. The separation in mean PI values
between placebo and active treatments is apparent early on Day 1,
persisting through Day 3 [Fig. 3(c)]. PI differences between tra-
madol/acetaminophen and placebo were statistically signiﬁcant
for ﬁve of the seven individual walks and were statistically
signiﬁcant for one of seven walks when compared between nap-
roxen and placebo. For the two walks that were non-signiﬁcant for
tramadol/acetaminophen, the P-values were 0.06 and 0.07. For the
naproxen vs placebo difference, one additional walk had P¼ 0.06.
When the outlier was excluded, both active treatments were
signiﬁcantly different from placebo for all walks (P-value range
0.001e0.022). Tramadol/acetaminophen was signiﬁcantly more
effective than placebo at the earliest treadmill walk at 2 h on Day 1
(LS mean 1.4 vs 0.8; P¼ 0.03). Naproxenwas signiﬁcantly better
than placebo beginning at the treadmill walk at 6 h on Day 1 (0.9
vs 0.2; P¼ 0.049).
TTMP
TTMP was signiﬁcantly improved (i.e., longer) for both trama-
dol/acetaminophen and naproxen than with placebo for all walks
on both Days 1 and 3 (Fig. 4). For Day 1 SP walks, the LS mean TTMP
was 17.8 minwith tramadol/acetaminophen (P< 0.001 vs placebo),
16.4 min with naproxen (P¼ 0.015 vs placebo), and 14.2 min with
placebo. For Day 3 SP walks, these values were 18.0 min (P¼ 0.002
vs placebo), 18.4 min (P< 0.001 vs placebo), and 14.6 min,
respectively.
WOMAC scores
For the effect on Day 1, the only signiﬁcant difference from
placebo (5.2) was for tramadol/acetaminophen (8.3) for
WOMAC physical function scale (P¼ 0.038) (Fig. 5). The effect of
naproxen (6.9) was not statistically different from placebo. For
Day 1 WOMAC pain walking on a ﬂat surface, scores were 10.0,
3.8, and 4.8 for tramadol/acetaminophen, naproxen, and
placebo, respectively (P> 0.05), and for WOMAC pain subscale,
9.0, 5.8, and 5.6, respectively (P> 0.05). For Day 3, however,
both naproxen and tramadol/acetaminophen were signiﬁcantly
better than placebo for all three measures; for WOMAC pain
walking on a ﬂat surface the scores were 23.4 for tramadol/
acetaminophen, 23.6 for naproxen, and 7.1 for placebo
(P¼ 0.003 vs tramadol/acetaminophen; P¼ 0.002 vs naproxen). For
WOMAC pain subscale, the values were 20.6, 23.8, and 6.8,
respectively (P¼ 0.003 vs tramadol/acetaminophen; P< 0.001 vs
naproxen). For WOMAC physical function subscale, the values were
18.7, 22.1, and 6.2, respectively (P¼ 0.002 vs tramadol/acet-
aminophen; P< 0.001 vs naproxen).
The correlations between the TWA change in PI for all treat-
ments and the three WOMAC measures were mild: r¼ 0.4
(P< 0.0001) for WOMAC pain walking on a ﬂat surface, r¼ 0.2High-pace Day 3 High-pace Day 1
Naproxen
(P-value)
Tramadol/
Acetaminophen
(P-value)
Naproxen
(P-value)
Tramadol/
Acetaminophen
(P-value)
0.875 (0.019) 1.07 (0.007) 0.658 (0.052) 1.15 (0.003)
1.15 (0.002) 1.28 (<0.001) 1.12 (<0.001) 1.54 (<0.001)
ndom effect and baseline PI as covariate) was used to compare both treatments with
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Fig. 3. Difference from placebo in PI. a. Difference from placebo in TWA change from baseline in PI on Days 1 and 3 (all patients). b. Difference from placebo in TWA change from
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WOMAC physical function subscale.
Safety
A total of six patients had 10 AEs. There were four drug-related
AEs: pruritis in a patient receiving naproxen, lightheadedness in
a patient receiving tramadol/acetaminophen, drowsiness in a patient
receiving tramadol/acetaminophen, and heartburn in a patient
receiving naproxen. One patient discontinued due to an AE: acute
gouty attack in a patient receiving tramadol/acetaminophen, which
was not believed to be drug-related. There were no serious AEs.*
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placebo.Discussion
In this study we evaluated the acute analgesic effect of
naproxen, tramadol/acetaminophen, and placebo in knee OA using
a novel walking model modiﬁed from a previous model used in
a truncated study17, which failed to show a difference between
a single dose of ibuprofen 800 mg and placebo during four 15-min
walks over 4 h. Reasons hypothesized for the failed study include
the lack of requirement for ﬂare after analgesic washout, insufﬁ-
cient walk duration, insufﬁcient overall observation time, and
insufﬁcient dosing duration. In the current study, we evaluated
single- andmultiple-dose response to two analgesics with different* * *
*† †
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We found that tramadol/acetaminophen was signiﬁcantly more
effective than placebo for the primary endpoint of TWA PI change
from baseline for SP walks on Day 3. Tramadol/acetaminophenwas
also signiﬁcantly more effective than placebo at the earliest time-
point of 2 h. When excluding the outlier patient, both active
treatments were signiﬁcantly more effective than placebo for all
evaluated endpoints. Both active treatments were also signiﬁcantly
better than placebo for TTMP for both SP and HP walks on Days 1
and 3. Signiﬁcant differences between active treatment and
placebo for WOMAC assessments were primarily noted only on
Day 3.
We observed single- and multiple-dose analgesic effects using
treadmill-induced PI measures for treatments with established
efﬁcacy in treating OA pain18,19. By including the WOMAC ques-
tionnaire, the endpoint most widely used for OA pain trials, we
show that both treadmill-induced pain andWOMAC questionnaires
pain subscale identify the treatment effects for both an NSAID and
an opiate on Day 3. Individual patient data showed that change in
treadmill-induced pain correlated with change in WOMAC pain
subscale, but only to a small degree (r¼ 0.2; P¼ 0.01). Moreover,
we utilized two different walk speeds to explore the relationship of
walk pace and pain. It is known that patients with OA walk more
slowly than healthy age-matched control subjects20, and that self-
selected pace is related to self-reported functional limitation21. PI
data for the two HP walks were compared with the SP walks
revealing LS mean PI for HP walks was greater than for SP walks (LS
mean difference w0.6 for each treatment, P< 0.001), indicating
that increasing pain during treadmill walks is not merely an
entrained response but reﬂects different levels of stimulus
intensity.
This performance-related walking model at self-selected pace
has additional beneﬁts in OA trial design and in identifying the
attributes of analgesic medications. Our primary analysis was based
on the active timed walks, which give a more objective measure of
painwith function over time. As previously reported, there appears
to be high and signiﬁcant correlation between the WOMAC pain
and physical function subscales22, suggesting that they represent
a single construct23. Because of this, and because pain appears to
drive physical function scores24,25, patients may report improved
WOMAC physical function scores despite worsening function on
objective performance measures, such as timed walks24,26,27. Thus,
our walking model helps overcome these potential shortcomings
by evaluating exertion-induced pain over the course of several
timed walks. Moreover, given both the factorial importance of
walking in the development of the WOMAC28,29as well as the
importance patients place on walking30,31 our ﬁndings of signiﬁ-
cantly prolonged TTMP further underscore the practical beneﬁts of
analgesic medications to allow additional functional performance
before meeting a patient-deﬁned threshold for discomfort. This
walking model may be used to further study the interrelationship
of pain andwalking performance in OA and the impact of analgesics
on both pain and performance domains.
In a previous study using a walking model in acute OA pain,
Moskowitz et al.11evaluated the effect of a single dose of rofecoxib
25 mg, valdecoxib 10 mg or placebo over a 6-h period comprising
eight 10-min walks post-dose. They found valdecoxib was signiﬁ-
cantly better than placebo beginning at 4 h and rofecoxib better
than placebo beginning at 5 h as measured by PI difference on
a 100-mm VAS. However, our model appears considerably more
efﬁcient, as our Day 1 results were generally comparable with
signiﬁcant improvements with tramadol/acetaminophen at 2 h
post-dose and with naproxen and at 6 h post-dose, but are
considerably more sensitive, as we studied 22 patients rather than
several hundred. The reasons for this greater sensitivity may bemultiple, as we used a crossover design to reduce variability,
controlled patient pace with a treadmill, required patients to
demonstrate worsening on treadmill walk-induced pain prior to
entry, employed longer walks, and measured single- and multiple-
dose effects.
The relative sensitivity of different efﬁcacy endpoints can be
quantiﬁed using the standardized effect size, which is the differ-
ence in treatment group means divided by the pooled SD, a reﬂec-
tion of treatment effect in relation to the underlying variability.
Meta-analyses have estimated effect sizes for NSAIDs and COX-2
selective inhibitors in OA of the hip or knee of 0.23e0.69 using the
WOMAC Questionnaire or Patient Global Assessment of Disease
Status endpoint32e34, indicating small-to-moderate changes
compared with placebo. Our prespeciﬁed primary endpoint for
treadmill walks on Day 3 yielded effect sizes of 0.5 and 0.6 for
naproxen and tramadol/acetaminophen, respectively. When
excluding the responses of one outlier patient, effect sizes
increased substantially to 0.9 and 1.2, respectively. The improved
power to observe treatment differences is illustrated by statistically
signiﬁcant effects of tramadol/acetaminophen on Day 1 with the
treadmill walk pain endpoints but not with the WOMAC pain
subscale. A more efﬁcient clinical trial design such as this walking
model may ﬁnd utility in testing novel analgesics in patient pop-
ulations and may be attractive for clinical researchers who have
access to unique patient populations or wish to combine pain
assessments with unique methodologies, such as imaging studies
or neurophysiologic assessments.
Acute pain relief in the context of an otherwise chronic disease
is an important and possibly overlooked aspect of OA treatment. As
such, this acute pain model may be relevant for the assessment of
agents with rapid effects on OA pain. Despite the chronic nature of
OA, clinical experience and prescription patterns show that many
patients do not use analgesics on a daily basis. Rather, they tend to
use them intermittently4e6. Hawker and colleagues characterized
both acute and constant features of the OA pain experience in focus
groups, showing each component can be distinguished, and that
the intermittent pain was more intense35. Further, each of the
mechanistic drug classes utilized in this study e acetaminophen,
opiate, NSAID e is utilized chronically OA pain and also has activity
in acute pain models such as third molar extraction, post-surgical
pain, and acute ligamentous sprains. The particular tramadol/
acetaminophen combination used in this study is intended for
short-term treatment of OA in some countries, so some regulatory
bodies understand the need for acute, intermittent treatment of OA
pain. Finally, the ﬂare design of most OA pain trials ewithdrawal of
treatment to allow the patients' pain toworsen prior to randomized
treatment assignment e demonstrates that this worsening of OA
pain is transient, as most placebo-controlled studies show the
resolution of the ﬂare (PI) in many placebo-treated patients.
Despite the importance of the acute pain component of the OA pain
experience, the onset of analgesia in OA pain is not heavily studied.
This clinical platform provides a tool with which to approach these
questions.
One limitation of this model is that we collectedWOMAC scores
at baseline and at the end of Days 1 and 3, but not before each
treadmill walk. Such data would have allowed us to compare the
TWA change in PI to the change in WOMAC scores over the same
periods, which would provide a better measure of the relative
sensitivities. Similarly, we did not collect any measure of on-
treatment patient global assessment, which would have allowed us
to further compare our model and WOMAC scores (e.g., as a recei-
vereoperator characteristic curve). In addition, it should be noted
that we compared naproxen, which is indicated for chronic
symptomatic treatment of OA, with tramadol/acetaminophen,
which is indicated for short-term (5 days) management of acute
E. Peeva et al. / Osteoarthritis and Cartilage 18 (2010) 646e653652pain only. Thus, the results of this 3-day study cannot be extrapo-
lated to chronic OA in general. Lastly, although each primary
hypothesis was considered separately, had we used a multiplicity
adjustment for the primary hypotheses, neither naproxen nor tra-
madol/acetaminophen would have been declared effective at 3
days. However, without the statistical outlier patient, both agents
would have been declared effective at 3 days evenwith multiplicity
adjustment, because both P-values were <0.01 and the Bonferroni
multiplicity adjustment would require both P-values to be <0.025.
Likewise, we performed multiple analyses to assess the sensitivity
and suitability of this walking model, but we did not adjust for
multiplicity for the secondary, exploratory, or post-hoc analyses.
These results should be interpreted accordingly and viewed as
hypothesis-generating. The totality of the data, considering effects
at Day 1 and across each of the individual walks (Table II, Fig. 3)
suggests that the model may be capable of discriminating active
analgesics from placebo after short exposure, which should facili-
tate the rapid development of novel agents.
In conclusion, this novel treadmill walking model to evaluate
acute analgesia in OA of the knee was able to discriminate active
analgesic treatments from placebo within 2 h of the ﬁrst dose and
at multiple timepoints over 3 days of treatment, with effect sizes
substantially larger than those observed with traditional OA trial
endpoints.
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